Kathmere Capital Management’s 10x Genomics TXG Stock Holding History

Kathmere Capital Management’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$257K	Buy	+6,697	New	+$176K	0.01%	559

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Kathmere Capital Management's TXG Position: Q2 2026 in Review

Kathmere Capital Management opened a new position in 10x Genomics (TXG) in Q2 2026: 6,697 shares worth $257K. The stake represents 0.01% of the portfolio and ranks #559 among its holdings.

390 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

Kathmere Capital Management held 6,697 shares of 10x Genomics worth $257K as of Q2 2026.
10x Genomics was a new Kathmere Capital Management position in Q2 2026.
10x Genomics made up 0.01% of Kathmere Capital Management's portfolio in Q2 2026, its #559 holding.
390 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Kathmere Capital Management's 13F filing for Q2 2026, filed 29 Jul 2026.